Expert Interview
A Second View: Delving into Affimed's innate cell engager AFM13 for treating CD30-positive lymphoma
Ticker(s): AFMDInstitution: Cleveland Clinic
- Director of the Lymphoid Malignancies Program, Staff Physician in the Cleveland Clinic Taussig Cancer Institute, & Associate Professor of Medicine of the Cleveland Clinic Lerner College of Medicine.
- Manages several hundred patients with lymphoma including several dozen CD30-positive Hodgkin lymphoma.
- Clinical and research focus is in chronic lymphocytic leukemia (CLL) and lymphoma; PIof multiple on-going clinical trials of new cancer treatments including novel cellular therapies and has published extensive research articles pertaining to these topics.
Please describe your clinical practice; how many patients with solid tumors do you treat on a yearly basis, what percent of your patients could benefit from upcoming novel drugs ? How much need is there for a tetravalent, bispecific innate cell engager such as AFM24?
Could you please explain to us the mechanism of action behind the drug’s ability to bind to CD16A on innate immune cells and EGFR, and how that translates into better patient outcomes? Where do you see the benefits of this approach vs standard of care?
Looking into the recent abstract presentations, could you please share with us thoughts regarding the upregulation of activation markers/ the transient loss of NK cells from peripheral blood/ migration of NK cells to the tumor?
Could you please tell us your thoughts regarding the BLA Denial and Withdrawal of Romidepsin, are there any parallels that could be drawn between that and AFM13 or AFM24?
How likely is it for AFM24 + Roche Atezolizumab 1PR (Gastric) or 1SD (Pancreatic) to become the preferred method of treatment, judging by the recent data?
The company has stated in the past that every patient overexpressing EGFR could be eligible for treatment with AFMD24 irrespective of mutational status. How would you rate that statement?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
